Xeris Biopharma Holdings Statistics
Total Valuation
XERS has a market cap or net worth of $965.62 million. The enterprise value is $1.11 billion.
Important Dates
The last earnings date was Monday, March 2, 2026, before market open.
| Earnings Date | Mar 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
XERS has 172.43 million shares outstanding. The number of shares has increased by 17.69% in one year.
| Current Share Class | 172.43M |
| Shares Outstanding | 172.43M |
| Shares Change (YoY) | +17.69% |
| Shares Change (QoQ) | +1.38% |
| Owned by Insiders (%) | 5.04% |
| Owned by Institutions (%) | 58.97% |
| Float | 163.74M |
Valuation Ratios
The trailing PE ratio is 1,736.76 and the forward PE ratio is 52.79.
| PE Ratio | 1,736.76 |
| Forward PE | 52.79 |
| PS Ratio | 3.30 |
| Forward PS | 2.49 |
| PB Ratio | 66.66 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 34.45 |
| P/OCF Ratio | 33.61 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 29.94, with an EV/FCF ratio of 39.71.
| EV / Earnings | 2,002.21 |
| EV / Sales | 3.80 |
| EV / EBITDA | 29.94 |
| EV / EBIT | 44.55 |
| EV / FCF | 39.71 |
Financial Position
The company has a current ratio of 2.19, with a Debt / Equity ratio of 18.85.
| Current Ratio | 2.19 |
| Quick Ratio | 1.48 |
| Debt / Equity | 18.85 |
| Debt / EBITDA | 5.73 |
| Debt / FCF | 9.24 |
| Interest Coverage | 0.86 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 4.40% |
| Return on Invested Capital (ROIC) | 6.06% |
| Return on Capital Employed (ROCE) | 9.09% |
| Weighted Average Cost of Capital (WACC) | 9.43% |
| Revenue Per Employee | $670,908 |
| Profits Per Employee | $1,274 |
| Employee Count | 435 |
| Asset Turnover | 0.83 |
| Inventory Turnover | 0.73 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +13.90% in the last 52 weeks. The beta is 0.97, so XERS's price volatility has been similar to the market average.
| Beta (5Y) | 0.97 |
| 52-Week Price Change | +13.90% |
| 50-Day Moving Average | 6.88 |
| 200-Day Moving Average | 6.87 |
| Relative Strength Index (RSI) | 28.89 |
| Average Volume (20 Days) | 2,339,606 |
Short Selling Information
The latest short interest is 17.02 million, so 9.87% of the outstanding shares have been sold short.
| Short Interest | 17.02M |
| Short Previous Month | 17.39M |
| Short % of Shares Out | 9.87% |
| Short % of Float | 10.39% |
| Short Ratio (days to cover) | 9.80 |
Income Statement
In the last 12 months, XERS had revenue of $291.85 million and earned $554,000 in profits. Earnings per share was $0.00.
| Revenue | 291.85M |
| Gross Profit | 249.28M |
| Operating Income | 24.90M |
| Pretax Income | 554,000 |
| Net Income | 554,000 |
| EBITDA | 37.05M |
| EBIT | 24.90M |
| Earnings Per Share (EPS) | $0.00 |
Full Income StatementBalance Sheet
The company has $111.04 million in cash and $258.10 million in debt, with a net cash position of -$147.06 million or -$0.85 per share.
| Cash & Cash Equivalents | 111.04M |
| Total Debt | 258.10M |
| Net Cash | -147.06M |
| Net Cash Per Share | -$0.85 |
| Equity (Book Value) | 13.69M |
| Book Value Per Share | 0.08 |
| Working Capital | 130.74M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $28.63 million and capital expenditures -$696,000, giving a free cash flow of $27.93 million.
| Operating Cash Flow | 28.63M |
| Capital Expenditures | -696,000 |
| Free Cash Flow | 27.93M |
| FCF Per Share | $0.16 |
Full Cash Flow StatementMargins
Gross margin is 85.41%, with operating and profit margins of 8.53% and 0.19%.
| Gross Margin | 85.41% |
| Operating Margin | 8.53% |
| Pretax Margin | 0.19% |
| Profit Margin | 0.19% |
| EBITDA Margin | 12.70% |
| EBIT Margin | 8.53% |
| FCF Margin | 9.57% |
Dividends & Yields
XERS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.69% |
| Shareholder Yield | -17.69% |
| Earnings Yield | 0.06% |
| FCF Yield | 2.90% |
Analyst Forecast
The average price target for XERS is $10.83, which is 93.39% higher than the current price. The consensus rating is "Buy".
| Price Target | $10.83 |
| Price Target Difference | 93.39% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 19.37% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
XERS has an Altman Z-Score of 0.44 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.44 |
| Piotroski F-Score | 7 |
